In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies
Improved Progression-Free Survival is One of the Greatest Unmet Needs in RCC, According to a New Report from Decision Resources
BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists agree that a therapy's effect on overall survival and disease progression are the attributes that most influences their decisions regarding prescribing in advanced renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Aveo Oncology/Astellas Pharma/Kyowa Hakko Kirin's Tivopath has advantages over currently used therapies on disease progression.
According to the DecisionBase 2013 report entitled A Promising Immunotherapy Is on the Horizon. What Attributes Does It Need to Trump the Angiogenesis and mTOR Inhibitors?, surveyed U.S. oncologists indicate that they would prescribe Tivopath to 30 percent of their pretreated advanced renal cell carcinoma patients. However, owing to its Phase III clinical trial design and delay in reaching the already crowded market behind Pfizer's Inlyta, Decision Resources forecasts that Tivopath will earn a more modest 11 percent patient share in the U.S. pretreated advanced renal cell carcinoma market by 2021.
The report also finds that surveyed oncologists and managed care organization (MCO) pharmacy directors indicate that improved overall survival and progression-free survival are the greatest unmet needs in pretreated advanced renal cell carcinoma. Interviewed thought leaders are optimistic that Bristol-Myers Squibb's nivolumab has the potential to improve overall survival and at least in part address this unmet need.
"The MCO pharmacy directors we surveyed are particularly receptive to new pretreated advanced renal cell carcinoma therapies that offer improvements in median overall survival over currently available therapies," said Decision Resources Analyst Samuel Mentzer. "While some emerging therapies, such as nivolumab, hold promise, we do not expect any will match the clinical improvement over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.